Legend Biotech

Legend Biotech is a global clinical-stage biotechnology enterprise that develops novel cell therapies for hematologic malignancies and solid tumors. In partnership with Janssen, the enterprise developed Carvykti, an FDA-approved dual-epitope CAR-T cell therapy targeting B-cell maturation antigen in patients with relapsed multiple myeloma. Through proprietary cellular engineering platforms and international manufacturing facilities, Legend Biotech advances personalized cellular immunotherapies globally.